Trial Profile
An Open-Label, Randomised, Parallel Group Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Doses of DS-1093a in Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 1093 (Primary)
- Indications Anaemia
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 18 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Nov 2014 New trial record